Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
复制标题
DOI：
10.1111/trf.16934
复制
发表时间：
2022-07
期刊：
影响因子：
2.9
通讯作者：
Roberts, David J.
中科院分区：
文献类型：
--
作者：
Harvala, Heli;Dung Nguyen;Simmonds, Peter;Lamikanra, Abigail A.;Tsang, Hoi Pat;Otter, Ashley;Maes, Piet;Webster, Mhairi;Clarkson, Adam;Kaloyirou, Fotini;Hopkins, Valerie;Laidlaw, Stephen M.;Carroll, Miles;Mora, Ana;Griffiths, Alexandra;MacLennan, Sheila;Estcourt, Lise;Roberts, David J.
关键词：
恢复期血浆（CP）疗法治疗COVID-19的治疗益处可能来自SARS-CoV-2的中和抗体（nAb）。为了研究抗原变异对CP中和效力的影响，我们比较了免疫前后先前感染SARS-CoV-2的CP供体中针对SARS-CoV-2原型和最近出现的毒株（包括Delta和Omicron）的nAb滴度。在Astra Zeneca或Pfizer疫苗接种前（n = 17）和接种一剂（n = 43）或两剂（n = 71）后，对既往SARS-CoV-2感染供体的样本进行了分析。通过活病毒微量中和试验测定针对武汉/野生型（WT）、α、β和δ SARS-CoV-2毒株的抗体滴度，而使用病灶减少中和试验测定针对Omicron的抗体滴度。通过Elecsys anti-SARS-CoV-2定量加标试验（Roche）测定抗加标抗体。未接种疫苗的供体显示抗WT的几何平均滴度（GMT）为148，抗α的几何平均滴度为80，但大多数未能中和β、δ和Omicron菌株。相比之下，在一次疫苗接种后，在接种疫苗的供体中观察到针对所有SARS-CoV-2毒株的高GMT（WT：703; Alpha：692; Beta：187; Delta：215; Omicron：434）。通过ROC分析，20，000 U/mL Roche定量Elecsys加标试验的反应性高度预测针对Delta的nAb滴度≥1：640（90%灵敏度; 97%特异性）和针对Omicron的nAb滴度≥1：320（89%灵敏度; 81%特异性）的献血者。对先前感染的CP供体接种疫苗可诱导高水平的针对SARS-CoV-2循环抗原变体的广泛中和抗体。通过自动定量抗刺突抗体测定法可以可靠地鉴定高滴度捐献物，从而实现高滴度恢复期血浆的大规模预选。
The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID‐19 may derive from neutralizing antibodies (nAbs) to SARS‐CoV‐2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging strains of SARS‐CoV‐2, including Delta and Omicron, in CP donors previously infected with SARS‐CoV‐2 before and after immunization. Samples were assayed from previously SARS‐CoV‐2 infected donors before (n = 17) and after one (n = 43) or two (n = 71) doses of Astra‐Zeneca or Pfizer vaccinations. Ab titers against Wuhan/wild type (WT), Alpha, Beta, and Delta SARS‐CoV‐2 strains were determined by live virus microneutralization assay while titers to Omicron used a focus reduction neutralization test. Anti‐spike antibody was assayed by Elecsys anti‐SARS‐CoV‐2 quantitative spike assay (Roche). Unvaccinated donors showed a geometric mean titer (GMT) of 148 against WT, 80 against Alpha but mostly failed to neutralize Beta, Delta, and Omicron strains. Contrastingly, high GMTs were observed in vaccinated donors against all SARS‐CoV‐2 strains after one vaccine dose (WT:703; Alpha:692; Beta:187; Delta:215; Omicron:434). By ROC analysis, reactivity in the Roche quantitative Elecsys spike assay of 20,000 U/mL was highly predictive of donations with nAb titers of ≥1:640 against Delta (90% sensitivity; 97% specificity) and ≥1:320 against Omicron (89% sensitivity; 81% specificity). Vaccination of previously infected CP donors induced high levels of broadly neutralizing antibodies against circulating antigenic variants of SARS‐CoV‐2. High titer donations could be reliably identified by automated quantitative anti‐spike antibody assay, enabling large‐scale preselection of high‐titer convalescent plasma.
登录
查看更多内容
大量冠状病毒病毒疾病（COVID-19）患者的死亡率显着降低，早期含有康复性血浆，其中含有高滴度的抗疾病抗毒剂急性呼吸综合症冠状病毒2（SARS-COV-2）SPIKE蛋白IgG。
DOI：
10.1016/j.ajpath.2020.10.008
发表时间：
2021-01
期刊：
The American journal of pathology
影响因子：
--
作者：
Salazar E;Christensen PA;Graviss EA;Nguyen DT;Castillo B;Chen J;Lopez BV;Eagar TN;Yi X;Zhao P;Rogers J;Shehabeldin A;Joseph D;Masud F;Leveque C;Olsen RJ;Bernard DW;Gollihar J;Musser JM
通讯作者：
Musser JM
DOI：
10.1093/infdis/jiab563
发表时间：
2022-03-15
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Nguyen D;Xiao J;Simmonds P;Lamikanra A;Odon V;Ratcliff J;Townsend A;Roberts DJ;Harvala H
通讯作者：
Harvala H
影响因子：
19
作者：
Harvala, Heli;Mehew, Jennifer;Zambon, Maria
通讯作者：
Zambon, Maria
影响因子：
64.8
作者：
Carreno, Juan Manuel;Alshammary, Hala;Krammer, Florian
通讯作者：
Krammer, Florian
DOI：
10.1056/nejmoa2033700
发表时间：
2021-02-18
期刊：
The New England journal of medicine
影响因子：
--
作者：
Libster R;Pérez Marc G;Wappner D;Coviello S;Bianchi A;Braem V;Esteban I;Caballero MT;Wood C;Berrueta M;Rondan A;Lescano G;Cruz P;Ritou Y;Fernández Viña V;Álvarez Paggi D;Esperante S;Ferreti A;Ofman G;Ciganda Á;Rodriguez R;Lantos J;Valentini R;Itcovici N;Hintze A;Oyarvide ML;Etchegaray C;Neira A;Name I;Alfonso J;López Castelo R;Caruso G;Rapelius S;Alvez F;Etchenique F;Dimase F;Alvarez D;Aranda SS;Sánchez Yanotti C;De Luca J;Jares Baglivo S;Laudanno S;Nowogrodzki F;Larrea R;Silveyra M;Leberzstein G;Debonis A;Molinos J;González M;Perez E;Kreplak N;Pastor Argüello S;Gibbons L;Althabe F;Bergel E;Polack FP;Fundación INFANT–COVID-19 Group
通讯作者：
Fundación INFANT–COVID-19 Group